Pfizer bolsters cancer portfolio with $10.64 billion deal for Array

Pfizer Inc said on Monday it would acquire Array Biopharma Inc for $10.64 billion in cash to beef up its cancer portfolio as it faces rising generic competition for its blockbuster drugs.